An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson’s disease

References

• Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;33(1):1–21. doi: 10.1038/nrdp.2017.13
   Google Scholar
• Ou Z, Pan J, Tang S, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019. Front Public Health. 2021;9:776847. doi: 10.3389/fpubh.2021.776847
   PubMed Web of Science ®Google Scholar
• Vuletic V, Racki V, Chudy D, et al. Deep brain stimulation in non-motor symptoms of neurodegenerative diseases. In: Neurostimulation and neuromodulation in contemporary therapeutic practice. IntechOpen; 2020.
   Google Scholar
• Angot E, Brundin P. Dissecting the potential molecular mechanisms underlying α-synuclein cell-to-cell transfer in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:S143–S147. doi: 10.1016/S1353-8020(09)70802-8
   PubMed Web of Science ®Google Scholar
• Giuliano C, Cerri S, Cesaroni V, et al. Relevance of biochemical deep phenotyping for a personalised approach to Parkinson’s disease. Neuroscience. 2023;511:100–109. doi: 10.1016/j.neuroscience.2022.12.019
   PubMed Web of Science ®Google Scholar
• Jankovic J, Tan EK. Parkinson’s disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795–808. doi: 10.1136/jnnp-2019-322338
   PubMed Web of Science ®Google Scholar
• Carrarini C, Russo M, Dono F, et al. A stage-based approach to therapy in parkinson’s disease. Biomolecules. 2019;9(8):388. doi: 10.3390/biom9080388
   PubMed Web of Science ®Google Scholar
• Hernández-Parra H, Cortés H, Avalos-Fuentes JA, et al. Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization. J Nanobiotechnology. 2022;20(1):413. doi: 10.1186/s12951-022-01612-5
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–2508.
   PubMed Web of Science ®Google Scholar
• Liu J-S, Chen Y, Shi D-D, et al. Pharmacogenomics—a New frontier for individualized treatment of Parkinson’sDisease. Curr Neuropharmacol. 2022;21(3):536–546. doi: 10.2174/1570159X21666221229154830
   Web of Science ®Google Scholar
• Politi C, Ciccacci C, Novelli G, et al. Genetics and treatment response in Parkinson’s disease: An Update on pharmacogenetic studies. Neuromol Med. 2018;20(1):1–17. doi: 10.1007/s12017-017-8473-7
   PubMed Web of Science ®Google Scholar
• Agúndez JAG, García-Martín E, Alonso-Navarro H, et al. Anti-Parkinson’s disease drugs and pharmacogenetic considerations. Expert Opinion On Drug Metabolism & Toxicology. 2013;9(7):859–874. doi: 10.1517/17425255.2013.789018
   PubMed Web of Science ®Google Scholar
• Aldred J, Nutt JG. Levodopa. Encyclopedia of movement disorders. Academic Press. 2010;p. 132–137. doi: 10.1016/B978-0-12-374105-9.00340-3
   Google Scholar
• Salat D, Tolosa E. Levodopa in the treatment of Parkinson’s disease: Current status and new developments. J Parkinsons Dis. 2013;3(3):255–269. doi: 10.3233/JPD-130186
   PubMedGoogle Scholar
• McLeod HL, Fang L, Luo X, et al. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther. 1994;270(1):26–29.
   PubMed Web of Science ®Google Scholar
• Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, et al. COMT gene and risk for Parkinson’s disease: A systematic review and meta-analysis. Pharmacogenet Genomics. 2014;24(7):331–339. doi: 10.1097/FPC.0000000000000056
   PubMed Web of Science ®Google Scholar
• Lachman HM, Papolos DF, Saito T, et al. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6(3):243–250. doi: 10.1097/00008571-199606000-00007
   PubMedGoogle Scholar
• Białecka M, Droździk M, Kłodowska-Duda G, et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson’s disease. Acta Neurol Scand. 2004;110(4):260–266. doi: 10.1111/j.1600-0404.2004.00315.x
   PubMed Web of Science ®Google Scholar
• Sampaio TF, dos Santos EUD, de Lima GDC, et al. MAO-B and COMT genetic variations associated with levodopa treatment response in patients with Parkinson’s disease. J Clin Pharmacol. 2018;58(7):920–926. doi: 10.1002/jcph.1096
   PubMed Web of Science ®Google Scholar
• Bialecka M, Kurzawski M, Klodowska-Duda G, et al. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet Genomics. 2008;18(9):815–821. doi: 10.1097/FPC.0b013e328306c2f2
   PubMed Web of Science ®Google Scholar
• Cheshire P, Bertram K, Ling H, et al. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson’s disease. Neurodegener Dis. 2013;13(1):24–28. doi: 10.1159/000351097
   PubMed Web of Science ®Google Scholar
• Lee MS, Lyoo CH, Ulmanen I, et al. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson’s disease. Neurosci Lett. 2001;298(2):131–134. doi: 10.1016/S0304-3940(00)01749-3
   PubMed Web of Science ®Google Scholar
• Contin M, Martinelli P, Mochi M, et al. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patient with parkinson’s disease. Mov Disord. 2005;20(6):734–739. doi: 10.1002/mds.20410
   PubMed Web of Science ®Google Scholar
• De Lau LML, Verbaan D, Marinus J, et al. Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson’s disease. Mov Disord. 2012;27(1):132–135. doi: 10.1002/mds.23805
   PubMed Web of Science ®Google Scholar
• Watanabe M, Harada S, Nakamura T, et al. Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson’s disease. Neuropsychobiology. 2003;48:190–193. doi: 10.1159/000074637
   PubMed Web of Science ®Google Scholar
• Vallelunga A, Flaibani R, Formento-Dojot P, et al. Role of genetic polymorphisms of the dopaminergic system in Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord. 2012;18(4):397–399. doi: 10.1016/j.parkreldis.2011.10.019
   PubMed Web of Science ®Google Scholar
• Frauscher B, Högl B, Maret S, et al. Association of daytime sleepiness with COMT polymorphism in patients with Parkinson disease: A pilot study. Sleep. 2004;27(4):733–736. doi: 10.1093/sleep/27.4.733
   PubMed Web of Science ®Google Scholar
• Redenšek S, Flisar D, Kojovic M, et al. Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson’s disease. Front Pharmacol. 2019;10:8. doi: 10.3389/fphar.2019.00008
   PubMed Web of Science ®Google Scholar
• Devos D, Lejeune S, Cormier-Dequaire F, et al. Dopa-decarboxylase gene polymorphisms affect the motor response to l-dopa in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(2):170–175. doi: 10.1016/j.parkreldis.2013.10.017
   PubMed Web of Science ®Google Scholar
• Kraemmer J, Smith K, Weintraub D, et al. Clinical-genetic model predicts incident impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2016;87(10):1106–1111. doi: 10.1136/jnnp-2015-312848
   PubMed Web of Science ®Google Scholar
• Rieck M, Schumacher-Schuh AF, Altmann V, et al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients. Pharmacogenomics. 2012;13(15):1701–1710. doi: 10.2217/pgs.12.149
   PubMed Web of Science ®Google Scholar
• Wang J, Liu ZL, Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology. 2001;56(12):1757–1759. doi: 10.1212/WNL.56.12.1757
   PubMed Web of Science ®Google Scholar
• Kaiser R, Hofer A, Grapengiesser A, et al. L-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology. 2003;60(11):1750–1755. doi: 10.1212/01.WNL.0000068009.32067.A1
   PubMed Web of Science ®Google Scholar
• dos Santos EUD, Sampaio TF, Tenório dos Santos AD, et al. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson’s disease. J Pharm Pharmacol. 2019;71(2):206–212. doi: 10.1111/jphp.13031
   PubMed Web of Science ®Google Scholar
• Lee JY, Cho J, Lee EK, et al. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson’s disease. Mov Disord. 2011;26(1):73–79. doi: 10.1002/mds.23400
   PubMed Web of Science ®Google Scholar
• Paus S, Seeger G, Brecht HM, et al. Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson’s disease. Mov Disord. 2004;19(6):705–707. doi: 10.1002/mds.20134
   PubMed Web of Science ®Google Scholar
• Rissling I, Geller F, Bandmann O, et al. Dopamine receptor gene polymorphisms in Parkinson’s disease patients reporting “sleep attacks”. Mov Disord. 2004;19(11):1279–1284. doi: 10.1002/mds.20245
   PubMed Web of Science ®Google Scholar
• Makoff AJ, Graham JM, Arranz MJ, et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson’s disease. Pharmacogenetics. 2000;10(1):43–48. doi: 10.1097/00008571-200002000-00006
   PubMedGoogle Scholar
• Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: An exploratory study. Arch Neurol. 2005;62(4):601–605. doi: 10.1001/archneur.62.4.601
   PubMed Web of Science ®Google Scholar
• Oliveri RL, Annesi G, Zappia M, et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology. 1999;53(7):1425–1430. doi: 10.1212/WNL.53.7.1425
   PubMed Web of Science ®Google Scholar
• Strong JA, Dalvi A, Revilla FJ, et al. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord. 2006;21(5):654–659. doi: 10.1002/mds.20785
   PubMed Web of Science ®Google Scholar
• Rieck M, Schumacher-Schuh AF, Altmann V, et al. Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson’s disease. Pharmacogenomics J. 2018;18(1):196–200. doi: 10.1038/tpj.2016.79
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy S, Rajan R, Banerjee M, et al. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson’s disease patients. Parkinsonism Relat Disord. 2016;30:13–17. doi: 10.1016/j.parkreldis.2016.06.005
   PubMed Web of Science ®Google Scholar
• Goetz CG, Burke PF, Leurgans S, et al. Genetic variation analysis in Parkinson disease patients with and without hallucinations: Case-control study. Arch Neurol. 2001;58(2):209–213. doi: 10.1001/archneur.58.2.209
   PubMedGoogle Scholar
• Becker ML, Visser LE, Van Schaik RHN, et al. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2011;12(1):79–82. doi: 10.1007/s10048-010-0254-5
   PubMed Web of Science ®Google Scholar
• Schumacher-Schuh AF, Francisconi C, Altmann V, et al. Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson’s disease. Int J Neuropsychopharmacol. 2013;16(6):1251–1258. doi: 10.1017/S1461145712001666
   PubMed Web of Science ®Google Scholar
• Moreau C, Meguig S, Corvol JC, et al. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease. Brain. 2015;138(5):1271–1283. doi: 10.1093/brain/awv063
   PubMedGoogle Scholar
• Altmann V, Schumacher-Schuh AF, Rieck M, et al. Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson’s disease. Pharmacogenomics. 2016;17:481–488. doi: 10.2217/pgs.15.183
   PubMed Web of Science ®Google Scholar
• Kaplan N, Vituri A, Korczyn AD, et al. Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson’s disease. J Mol Neurosci. 2014;53(2):183–188. doi: 10.1007/s12031-014-0276-9
   PubMed Web of Science ®Google Scholar
• Purcaro C, Vanacore N, Moret F, et al. DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson’s disease. Neurosci Lett. 2019;690:83–88. doi: 10.1016/j.neulet.2018.10.021
   PubMed Web of Science ®Google Scholar
• Schumacher-Schuh AF, Altmann V, Rieck M, et al. Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson’s disease patients. Pharmacogenomics J. 2014;14(3):289–294. doi: 10.1038/tpj.2013.37
   PubMed Web of Science ®Google Scholar
• Corvol JC, Bonnet C, Charbonnier-Beaupel F, et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson’s disease: a randomized crossover clinical trial. Ann Neurol. 2011;69(1):111–118. doi: 10.1002/ana.22155
   PubMed Web of Science ®Google Scholar
• Chong DJ, Suchowersky O, Szumlanski C, et al. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson’s disease. Clin Neuropharmacol. 2000;23(3):143–148. doi: 10.1097/00002826-200005000-00003
   PubMed Web of Science ®Google Scholar
• Ferrari M, Martignoni E, Blandini F, et al. Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson’s disease patients. Eur J Clin Pharmacol. 2012;68(11):1493–1499. doi: 10.1007/s00228-012-1281-y
   PubMed Web of Science ®Google Scholar
• Acuña G, Foernzler D, Leong D, et al. Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J. 2002;2(5):327–334. doi: 10.1038/sj.tpj.6500123
   PubMedGoogle Scholar
• Masellis M, Collinson S, Freeman N, et al. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain. 2016;139(7):2050–2062. doi: 10.1093/brain/aww109
   PubMedGoogle Scholar
• Arbouw MEL, Movig KLL, Egberts TCG, et al. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease. Eur J Clin Pharmacol. 2009;65(12):1245–1251. doi: 10.1007/s00228-009-0708-6
   PubMed Web of Science ®Google Scholar
• Liu YZ, Tang BS, Yan XX, et al. Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson’s disease patients. Eur J Clin Pharmacol [Internet]. 2009;65:679–683. doi: 10.1007/s00228-009-0658-z
   PubMed Web of Science ®Google Scholar
• Xu S, Liu J, Yang X, et al. Association of the DRD2 CAn-STR and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response to dopamine agonists. J Neurol Sci. 2017;372:433–438. doi: 10.1016/j.jns.2016.08.005
   PubMed Web of Science ®Google Scholar
• Kalinderi K, Fidani L, Katsarou Z, et al. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson’s disease. Int J Clin Pract. 2011;65(12):1289–1294. doi: 10.1111/j.1742-1241.2011.02793.x
   PubMed Web of Science ®Google Scholar
• Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: A practical tutorial. Evid Based Ment Health. 2019;22(4):153–160. doi: 10.1136/ebmental-2019-300117
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45:139–145. doi: 10.1016/j.cct.2015.09.002
   PubMed Web of Science ®Google Scholar
• Hedges LV. Meta-analysis. J Educ Behav Stat. 1992;17(4):279–296. doi: 10.3102/10769986017004279
   Web of Science ®Google Scholar
• Wilkins RC, Lis JT. GAGA factor binding to DNA via a single trinucleotide sequence element. Nucleic Acids Res. 1998;26(11):2672–2678. doi: 10.1093/nar/26.11.2672
   PubMed Web of Science ®Google Scholar
• Boørglum AD, Kirov G, Craddock N, et al. Possible parent-of-origin effect of dopa decarboxylase in susceptibility to bipolar affective disorder. Am J Med Genet. 2003;117B:18–22. doi: 10.1002/ajmg.b.10030
   PubMed Web of Science ®Google Scholar
• Kurzawski M, Białecka M, Droździk M. Pharmacogenetic considerations in the treatment of Parkinson’s disease. Neurodegener Dis Manag. 2015;5(1):27–35. doi: 10.2217/nmt.14.38
   PubMedGoogle Scholar
• Paus S, Grünewald A, Klein C, et al. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson’s disease. Mov Disord. 2008;23(4):599–602. doi: 10.1002/mds.21901
   PubMed Web of Science ®Google Scholar
• Baik JH. Dopamine signaling in food addiction: role of dopamine D2 receptors. BMB Rep. 2013;46(11):519–526. doi: 10.5483/BMBRep.2013.46.11.207
   PubMed Web of Science ®Google Scholar
• Clinical Annotation for rs1799732 (DRD2); levodopa; Parkinson Disease (level 3 Toxicity) [Internet]. [cited 2023 Mar 16]. Available from: https://www.pharmgkb.org/clinicalAnnotation/1448525458
   Google Scholar
• Jeanneteau F, Funalot B, Jankovic J, et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006;103(28):10753–10758. doi: 10.1073/pnas.0508189103
   PubMed Web of Science ®Google Scholar
• Clinical Annotation for rs6280 (DRD3); levodopa; gastrointestinal toxicity, Hallucinations and Parkinson Disease (level 3 Toxicity) [Internet]. [cited 2023 Mar 15]. Available from: https://www.pharmgkb.org/clinicalAnnotation/1448525452
   Google Scholar
• Vuletić V, Rački V, Papić E, et al. A systematic review of parkinson’s disease pharmacogenomics: Is there time for translation into the clinics? Int J Mol Sci. 2021;22(13):7213. doi: 10.3390/ijms22137213
   PubMed Web of Science ®Google Scholar
• Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 2004;308(1):2–9. doi: 10.1124/jpet.103.053298
   PubMed Web of Science ®Google Scholar
• Clinical Annotation for rs622342 (SLC22A1); amantadine, Anticholinergics, Dopamine agonists, levodopa or selegiline; Parkinson Disease (level 3 Dosage, Toxicity) [Internet]. [cited 2023 Mar 16]. Available from: https://www.pharmgkb.org/clinicalAnnotation/1448101086
   Google Scholar
• van de Giessen EM, de Win MML, Tanck MWT, et al. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med. 2009;50(1):45–52. doi: 10.2967/jnumed.108.053652
   PubMed Web of Science ®Google Scholar
• Clinical Annotation for rs3836790 (SLC6A3); levodopa; Parkinson Disease (level 3 Efficacy) [Internet]. [cited 2023 Mar 16]. Available from: https://www.pharmgkb.org/clinicalAnnotation/1444703906
   Google Scholar
• Feldman B, Chapman J, Korczyn AD. Apolipoprotein ε4 advances appearance of psychosis in patients with Parkinson’s disease. Acta Neurol Scand. 2006;113(1):14–17. doi: 10.1111/j.1600-0404.2005.00535.x
   PubMed Web of Science ®Google Scholar
• Fujii C, Harada S, Ohkoshi N, et al. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson’s disease. Clinical Genetics. 1999;56(5):395–400. doi: 10.1034/j.1399-0004.1999.560508.x
   Web of Science ®Google Scholar
• Rieck M, Schumacher-Schuh AF, Callegari-Jacques SM, et al. Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson’s disease patients? Pharmacogenomics. 2015;16. doi: 10.2217/pgs.15.23
   PubMed Web of Science ®Google Scholar
• Clinical Annotation for rs4704559 (HOMER1); levodopa; Parkinson Disease (level 3 Toxicity) [Internet]. [cited 2023 Mar 16]. Available from: https://www.pharmgkb.org/clinicalAnnotation/1444680131
   Google Scholar
• Erga AH, Dalen I, Ushakova A, et al. Dopaminergic and opioid pathways associated with impulse control disorders in Parkinson’s disease. Front Neurol. 2018;9:109. doi: 10.3389/fneur.2018.00109
   PubMed Web of Science ®Google Scholar
• Borges N. Tolcapone in Parkinson’s disease: Liver toxicity and clinical efficacy. Expert Opin Drug Saf. 2005;4(1):69–73. doi: 10.1517/14740338.4.1.69
   PubMedGoogle Scholar
• Kiss LE, Soares-Da-Silva P. Medicinal chemistry of catechol O -methyltransferase (COMT) inhibitors and their therapeutic utility. J Med Chem. 2014;57(21):8692–8717. doi: 10.1021/jm500572b
   PubMed Web of Science ®Google Scholar
• Loureiro AI, Rocha F, Santos AT, et al. Absorption, metabolism and excretion of opicapone in human healthy volunteers. Br J Clin Pharmacol. 2022;88(10):4540–4551. doi: 10.1111/bcp.15383
   PubMed Web of Science ®Google Scholar
• Clinical Annotation for rs4680 (COMT); entacapone; Parkinson Disease (level 3 Efficacy) [Internet]. [cited 2023 Mar 17]. Available from: https://www.pharmgkb.org/clinicalAnnotation/1444704400
   Google Scholar
• Villeneuve L, Girard H, Fortier LC, et al. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther. 2003;307(1):117–128. doi: 10.1124/jpet.103.054072
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Nakajima M, Katoh M, et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics. 2004;14(5):329–332. doi: 10.1097/00008571-200405000-00008
   PubMedGoogle Scholar
• Kalgutkar AS, Dalvie DK, Castagnoli N, et al. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes a and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol. 2001;14(9):1139–1162. doi: 10.1021/tx010073b
   PubMed Web of Science ®Google Scholar
• Foley P, Gerlach M, Youdim MBH, et al. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord. 2000;6(1):25–47. doi: 10.1016/S1353-8020(99)00043-7
   PubMed Web of Science ®Google Scholar
• Schapira AHV, Fox SH, Hauser RA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations a randomized clinical trial. JAMA Neurol. 2017;74(2):216–224. doi: 10.1001/jamaneurol.2016.4467
   PubMed Web of Science ®Google Scholar
• Jessen L, Kovalick LJ, Azzaro AJ. The selegiline transdermal system (Emsam): a therapeutic option for the treatment of major depressive disorder. P And T. 2008;33(4):212–246.
   PubMedGoogle Scholar
• Puttrevu SK, Arora S, Polak S, et al. Physiologically based pharmacokinetic modeling of transdermal selegiline and its metabolites for the evaluation of disposition differences between healthy and special populations. Pharmaceutics. 2020;12(10):942. doi: 10.3390/pharmaceutics12100942
   PubMed Web of Science ®Google Scholar
• Guay DRP. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson’s disease. Am J Geriatr Pharmacother. 2006;4(4):330–346. doi: 10.1016/j.amjopharm.2006.12.001
   PubMedGoogle Scholar
• Carrascal-Laso L, Isidoro-García M, Ramos-Gallego I, et al. Review: influence of the cyp450 genetic variation on the treatment of psychotic disorders. J Clin Med. 2021;10(18):4275. doi: 10.3390/jcm10184275
   PubMed Web of Science ®Google Scholar
• Clinical Annotation for rs1076560 (DRD2); rasagiline; Parkinson Disease (level 3 Efficacy) [Internet]. [cited 2023 Mar 17]. Available from: https://www.pharmgkb.org/clinicalAnnotation/1448100444
   Google Scholar
• Clinical Annotation for rs2283265 (DRD2); rasagiline; Parkinson Disease (level 3 Efficacy) [Internet]. [cited 2023 Mar 17]. Available from: https://www.pharmgkb.org/clinicalAnnotation/1448100464
   Google Scholar
• Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinsonʼs disease. CNS Drugs. 1996;5(5):369–388. doi: 10.2165/00023210-199605050-00006
   PubMed Web of Science ®Google Scholar
• Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. Neurology. 1999;53:364–370. doi: 10.1212/WNL.53.2.364
   PubMed Web of Science ®Google Scholar
• Clinical Annotation for rs6280 (DRD3); pramipexole; Parkinson Disease (level 3 Efficacy) [Internet]. [cited 2023 Mar 17]. Available from: https://www.pharmgkb.org/clinicalAnnotation/655385037
   Google Scholar
• Theken KN, Lee CR, Gong L, et al. Clinical pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal anti-Inflammatory drugs. Clin Pharmacol Ther. 2020;108(2):191–200. doi: 10.1002/cpt.1830
   PubMed Web of Science ®Google Scholar
• Rocha JF, Almeida L, Falcão A, et al. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76(5):763–775. doi: 10.1111/bcp.12081
   PubMed Web of Science ®Google Scholar
• Bette S, Shpiner DS, Singer C, et al. Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: A review of the current clinical evidence. Ther Clin Risk Manag. 2018;14:1737–1745.
   PubMed Web of Science ®Google Scholar
• Baker DE, Kim AP. Formulary drug review: Safinamide. Hosp Pharm. 2017;52(8):532–543. doi: 10.1177/0018578717726046
   PubMedGoogle Scholar
• Leuratti C, Sardina M, Ventura P, et al. Disposition and metabolism of safinamide, a novel drug for parkinson’s disease, in healthy male volunteers. Pharmacology. 2013;92:207–216. doi: 10.1159/000354805
   PubMed Web of Science ®Google Scholar
• Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative study group. Neurology. 1997;48(2):363–368. doi: 10.1212/WNL.48.2.363
   PubMed Web of Science ®Google Scholar
• Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet. 2003;42(7):633–645. doi: 10.2165/00003088-200342070-00003
   PubMed Web of Science ®Google Scholar
• Via MA, Chandra H, Araki T, et al. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndr Obesity. 2010;3:43–48. doi: 10.2147/DMSO.S9575
   PubMedGoogle Scholar
• Blin O. The pharmacokinetics of pergolide in Parkinsonʼs disease. Curr Opin Neurol. 2003;16(Suppl 1):S9–12. doi: 10.1097/00019052-200312001-00003
   PubMedGoogle Scholar
• Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000;39(4):243–254. doi: 10.2165/00003088-200039040-00001
   PubMed Web of Science ®Google Scholar
• Singh R, Parmar M. StatPearls. Pramipexole. Orlando, Florida, United States: StatPearls Publishing; 2023.
   Google Scholar
• Contin M, Lopane G, Mohamed S, et al. Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2019;61:111–117. doi: 10.1016/j.parkreldis.2018.11.007
   PubMed Web of Science ®Google Scholar
• Elshoff JP, Cawello W, Andreas JO, et al. No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine. Clin Pharmacol Drug Dev. 2014;3(3):187–193. doi: 10.1002/cpdd.78
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Parkinson’s disease: from pathogenesis to Pharmacogenomics. Int J Mol Sci. 2017;18(3):551. doi: 10.3390/ijms18030551
   PubMed Web of Science ®Google Scholar
• Crews KR, Monte AA, Huddart R, et al. Clinical pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021;110(4):888–896. doi: 10.1002/cpt.2149
   PubMed Web of Science ®Google Scholar
• Contin M, Lopane G, Belotti LMB, et al. Sex is the main determinant of levodopa clinical pharmacokinetics: evidence from a large series of levodopa therapeutic monitoring. J Parkinsons Dis. 2022;12(8):2519–2530. doi: 10.3233/JPD-223374
   PubMedGoogle Scholar
• Mehanna R, Jankovic J. Young-onset Parkinson’s disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord. 2019;65:39–48. doi: 10.1016/j.parkreldis.2019.06.001
   PubMed Web of Science ®Google Scholar
• Wan Z, Wang X, Ma H, et al. Risk factors for motor complications in female patients with Parkinson’s disease. Neurol Sci. 2022;43(8):4735–4743. doi: 10.1007/s10072-022-05959-3
   PubMed Web of Science ®Google Scholar
• Scott NW, Macleod AD, Counsell CE. Motor complications in an incident Parkinson’s disease cohort. Eur J Neurol. 2016;23(2):304–312. doi: 10.1111/ene.12751
   PubMed Web of Science ®Google Scholar
• Bjornestad A, Forsaa EB, Pedersen KF, et al. Risk and course of motor complications in a population-based incident Parkinson’s disease cohort. Parkinsonism Relat Disord. 2016;22:48–53. doi: 10.1016/j.parkreldis.2015.11.007
   PubMed Web of Science ®Google Scholar
• Chung SJ, Lee Y, Lee JJ, et al. Rapid eye movement sleep behaviour disorder and striatal dopamine depletion in patients with Parkinson’s disease. Eur J Neurol. 2017;24(10):1314–1319. doi: 10.1111/ene.13388
   PubMed Web of Science ®Google Scholar
• van Deursen DN, van den Heuvel OA, Booij J, et al. Autonomic failure in Parkinson’s disease is associated with striatal dopamine deficiencies. J Neurol. 2020;267:1922–1930. doi: 10.1007/s00415-020-09785-5
   PubMed Web of Science ®Google Scholar
• Vriend C, van Balkom TD, van Druningen C, et al. Processing speed is related to striatal dopamine transporter availability in Parkinson’s disease. NeuroImage Clin. 2020;26:102257. doi: 10.1016/j.nicl.2020.102257
   PubMed Web of Science ®Google Scholar
• Haapaniemi TH, Ahonen A, Torniainen P, et al. [123]β-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord. 2001;16(1):124–130. doi: 10.1002/1531-8257(200101)16:1<124:AID-MDS1007>3.0.CO;2-R
   PubMed Web of Science ®Google Scholar
• Picconi B, Paillé V, Ghiglieri V, et al. L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis. 2008;29(2):327–335. doi: 10.1016/j.nbd.2007.10.001
   PubMed Web of Science ®Google Scholar
• Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008;9(9):665–677. doi: 10.1038/nrn2471
   PubMed Web of Science ®Google Scholar
• Cross B, Turner R, Pirmohamed M. Polygenic risk scores: An overview from bench to bedside for personalised medicine. Front Genet. 2022;13:1000667. doi: 10.3389/fgene.2022.1000667
   PubMed Web of Science ®Google Scholar
• Simona A, Song W, Bates DW, et al. Polygenic risk scores in pharmacogenomics: opportunities and challenges—a mini review. Front Genet. 2023;14:1217049. doi: 10.3389/fgene.2023.1217049
   PubMed Web of Science ®Google Scholar